Leading Chinese medical devices maker Mindray Medical International Limited (MR) has secured the 510 (k) clearance from the U.S. Food and Drug Administration (“FDA”) for its new anesthesia system. The device, dubbed the A5 Anesthesia System, represents the first in a new generation of anesthesia machines from the Shenzhen-based company.
Armed with state-of-the art design and the most intuitive user interface, the A5 offers an array of advanced ventilation modes which enable effective care across different patient acuity types. Its wide 15-inch touch screen facilitates rapid and easy selection of ventilation settings, which simplify workflow and enable physicians to devote more time to patient care.
The novel A5 anesthesia delivery platform represents another example of Mindray’s sustained R&D commitment to provide clinicians with the latest technology for enhancing patient care. The company met its product development goals for 2010, having launched 10 new products during the year.
Mindray recently outlined its pipeline strategy for 2011. The company plans to beef up product innovation by lifting its R&D investment in 2011 and aims to introduce 7-10 new products during the year with areas of product expansion including patient monitoring, defibrillator, anesthesia delivery and blood analysis.
Mindray is a global Chinese medical devices company holding a roughly 40% share of the Chinese healthcare market. The company offers its anesthesia machines through the “Patient Monitoring and Life Support Products” division, its largest segment. Mindray competes with global devices manufacturers such as General Electric (GE), Philips (PHG) and Siemens (SI).
Mindray has a strong position in the low and mid segments of the medical devices market in China and is poised to benefit from the solid fundamentals of the Chinese health care sector. Its new product development initiatives, expanding international footprint (and revenues) and solid sales infrastructure remain encouraging.
Although Mindray’s strength is currently in the low and mid-end segments, the company is looking to carve a niche in the high-end markets. Moreover, Mindray is well positioned to benefit from the health care reforms in China. However, the company is exposed to intense competition-driven pricing pressure.
GENL ELECTRIC (GE): Free Stock Analysis Report
MINDRAY MEDICAL (MR): Free Stock Analysis Report
KONINKLIJKE PHL (PHG): Free Stock Analysis Report
SIEMENS AG-ADR (SI): Free Stock Analysis Report
Zacks Investment Research
